Phase 2 trial of GO-203 in combination with decitabine for patients with AML who (i) are not candidates for induction chemotherapy, or (ii) have relapsed/refractory disease
(current)
Phase 1b trial of GO-203 in combination with decitabine for patients with relapsed/refractory AML
(completed)
Phase 1b trial of GO-203 for patients with relapsed/refractory AML
(completed)
GO-203
(completed)
(current)
Phase 1b trial of GO-203 in combination with decitabine for patients with relapsed/refractory AML
(completed)
- established acceptable safety profile (toxicity and efficacy)
Phase 1b trial of GO-203 for patients with relapsed/refractory AML
(completed)
- established acceptable safety profile (toxicity and efficacy)
GO-203
(completed)
- for patients with advanced solid tumors or lymphomas
- established acceptable safety profile (toxicity and efficacy)
- full details and results